These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 31021596

  • 1. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
    Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, Herring LE, Gilbert TSK, East MP, McDonald IM, Lockett MR, Ashamalla H, Moorman NJ, Karanewsky DS, Iwanowicz EJ, Holmuhamedov E, Graves LM.
    ACS Chem Biol; 2019 May 17; 14(5):1020-1029. PubMed ID: 31021596
    [Abstract] [Full Text] [Related]

  • 2. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS.
    Neoplasia; 2020 Dec 17; 22(12):725-744. PubMed ID: 33142238
    [Abstract] [Full Text] [Related]

  • 3. Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development.
    Jacques S, van der Sloot AM, C Huard C, Coulombe-Huntington J, Tsao S, Tollis S, Bertomeu T, Culp EJ, Pallant D, Cook MA, Bonneil E, Thibault P, Wright GD, Tyers M.
    Genetics; 2020 Apr 17; 214(4):1103-1120. PubMed ID: 32094149
    [Abstract] [Full Text] [Related]

  • 4. Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.
    Fennell EMJ, Aponte-Collazo LJ, Pathmasiri W, Rushing BR, Barker NK, Partridge MC, Li YY, White CA, Greer YE, Herring LE, Lipkowitz S, Sumner SCJ, Iwanowicz EJ, Graves LM.
    Front Pharmacol; 2023 Apr 17; 14():1136317. PubMed ID: 37063293
    [Abstract] [Full Text] [Related]

  • 5. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.
    Cell Cycle; 2018 Apr 17; 17(4):468-478. PubMed ID: 29157092
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS.
    Neoplasia; 2018 Jan 17; 20(1):80-91. PubMed ID: 29216597
    [Abstract] [Full Text] [Related]

  • 9. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS.
    Mol Cancer; 2015 May 01; 14():99. PubMed ID: 25927855
    [Abstract] [Full Text] [Related]

  • 10. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS.
    Oncotarget; 2016 Nov 08; 7(45):74380-74392. PubMed ID: 27602582
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y, Zhou L, Safran H, Borsuk R, Lulla R, Tapinos N, Seyhan AA, El-Deiry WS.
    Neoplasia; 2021 Aug 08; 23(8):792-810. PubMed ID: 34246076
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro.
    Zhang J, Luo B, Sui J, Qiu Z, Huang J, Yang T, Luo Y.
    Biochem Pharmacol; 2022 Oct 08; 204():115232. PubMed ID: 36030831
    [Abstract] [Full Text] [Related]

  • 16. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
    Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS.
    PLoS One; 2017 Oct 08; 12(8):e0180541. PubMed ID: 28767654
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J, Kline CL, Zhou L, Khazak V, El-Deiry WS.
    J Exp Clin Cancer Res; 2018 Jan 22; 37(1):11. PubMed ID: 29357916
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor.
    Free RB, Cuoco CA, Xie B, Namkung Y, Prabhu VV, Willette BKA, Day MM, Sanchez-Soto M, Lane JR, Laporte SA, Shi L, Allen JE, Sibley DR.
    Mol Pharmacol; 2021 Oct 22; 100(4):372-387. PubMed ID: 34353882
    [Abstract] [Full Text] [Related]

  • 19. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
    Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J.
    Neoplasia; 2017 Oct 22; 19(10):772-780. PubMed ID: 28863346
    [Abstract] [Full Text] [Related]

  • 20. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.
    Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M.
    Cancer Cell; 2019 May 13; 35(5):721-737.e9. PubMed ID: 31056398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.